Australia
GPN Vaccines is a biotechnology startup founded in 2017 with the aim of developing a broad-spectrum vaccine against Streptococcus pneumoniae. The company's slogan "Developing a broad-spectrum vaccine against Streptococcus pneumoniae, the world's foremost bacterial pathogen" reflects its primary focus. Currently, existing vaccines only protect against 20 of the 100 known strains of S. pneumoniae, leaving a significant gap in protection. This is a significant issue as S. pneumoniae causes life-threatening conditions such as pneumonia, meningitis, sepsis, and otitis media, contributing to up to two million deaths worldwide each year.
GPN Vaccines' goal is to address this gap by developing a novel, whole-cell vaccine that can provide broad-spectrum protection for both adults and children against S. pneumoniae, regardless of the strain. Their innovative approach has garnered attention, culminating in a recent $9.00M Series A investment on 31 January 2023 led by Forepont Capital Partners. This investment highlights the confidence that industry players have in GPN Vaccines' potential to revolutionize the fight against S. pneumoniae.
Headquartered in Australia, GPN Vaccines is positioned at the forefront of biotechnological advancements, aiming to make a significant impact on global health. With the support of their recent investment, the company is well-positioned to continue their groundbreaking work and bring their broad-spectrum vaccine to market, potentially saving countless lives.
